Emergency Contraception Actual Use Study

Phase 3

Completed

Brief Summary: This is a non-comparative case series study to assess the ability of females 11-16 years of age, inclusive, who are requesting emergency contraception (EC) to use the study product, DR-104 (Plan B® 1.5), appropriately and safely without provider counseling.

Detailed Description: To simulate an over-the-counter (OTC) setting, each potential subject was expected to read the label text on the outside of the study package and determine whether and how to use the study product without provider direction or assistance. The study product, Plan B® 1.5, was to be dispensed only to those subjects who appropriately self-selected and indicated that they wanted to participate in the study and receive study product. Subjects could also appropriately self-select not to use the study product.

Follow-up contact was to be conducted at approximately one, four, and eight weeks following the date the subject was dispensed study product. At these contacts, subjects answered questions regarding product use, health problems since last contact, and pregnancy status. Subjects were not to be permitted to enroll more than once in this Actual Use Study, however to assess repeat use of emergency contraceptives (EC) (use in addition to the study product) subjects were also queried at the one-, four-, and eight-week follow-up contacts regarding use of additional EC.

Recruitment & Eligibility

Inclusion Criteria

Female and 11-16 years of age, inclusive
Subject must be requesting emergency contraception for her own use (not for use by another person) and for current (not future) use
Subject can read and understand English, according to her own judgment
Others as dictated by FDA-approved protocol

Exclusion Criteria

Not provided

Arm && Interventions

Group	Intervention	Description
DR-104	DR-104	One tablet for emergency contraception

Primary Outcome Measures

Name	Time	Method
Percentage of Participants Who Appropriately Self-selected DR-104 (Plan B® 1.5) When Dispensed Under Simulated Over-the-counter (OTC) Conditions	Day 1	The percentage of participants who appropriately self-selected Plan B® 1.5 at the Screening/Enrollment Visit after reading the product label. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-diagnose the condition and that treatment with the product is appropriate for them.
Percentage of Participants Who Correctly Used DR-104 When Dispensed Under Simulated OTC Conditions	Week 1	The percentage of participants who having appropriately self-selected and been dispensed Plan B® 1.5, correctly used it according to product labeling. Correct use was considered to have occurred if participants reported at the Week 1 follow-up contact that she took Plan B® 1.5 within 72 hours following unprotected sexual intercourse. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-treat with the product according to the product instructions.

Secondary Outcome Measures

Name	Time	Method
Participants With Treatment-Emergent Adverse Events (TEAE)	Day 1 to week 8	Treatment-emergent adverse events included adverse events reported during the protocol-specified following up contacts at weeks 1, 4 and 8 or at any other participant contact for participants who took study drug.
Participants Summarized by Repeat Use of Emergency Contraception (EC)	up to week 8	As each participant dispensed Plan B® 1.5 was only given one tablet, repeat use of emergency contraception (EC) indicates use of an EC product other than the study product. Categories reflect the number of repeat uses.

Locations (2): Duramed Research Investigational Site
🇺🇸
Philadelphia, Pennsylvania, United States
Teva Investigational Site
🇺🇸
Pittsburgh, Pennsylvania, United States